source
- HHS to allow compounders to make 6 unapproved peptidesRFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested recommendation from outside advisers to the FDA in July.BioPharma Dive · 12d ago↗ source
- Genmab's bispecific combo with Keytruda halves death risk in phase 3 head‑neck cancer trialGenmab announced interim results from its phase 3 LiGeR-HN1 study, showing that adding the bispecific antibody petosemtamab to Merck's Keytruda significantly improved outcomes for patients with PD-…